Crossmark

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study

Crossref DOI link: https://doi.org/10.1186/s12933-018-0730-z

Published Online: 2018-06-12

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shigiyama, Fumika

Kumashiro, Naoki https://orcid.org/0000-0002-5432-3599
Fuchigami, Ayako

Hirose, Takahisa
Clinical Trials ^BETA

Clinical trials referenced in this document:

umin000028014 at UMIN Japan

Documents that mention this clinical trial

Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
https://doi.org/10.1186/s12933-019-0977-z

Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
https://doi.org/10.1186/s12933-018-0730-z
Funding

Funding for this research was provided by:

Astrazeneca Japan K.K.
License Information

Text and Data Mining valid from 2018-06-12

Version of Record valid from 2018-06-12
More Information

Article History

Received: 26 April 2018

Accepted: 6 June 2018

First Online: 12 June 2018

Document is current

Any future updates will be listed below